Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients

Phase 2positiveSKY-0515Positive

AI Analysis

Summary

Skyhawk Therapeutics announced fifteen-month final results from its Phase 1/2 trial of SKY-0515 in Huntington's Disease patients, showing a +1.59-point improvement in cUHDRS change from baseline at the Month 15 primary timepoint.

Clinical Trial Data

Phase

Phase 1/2

Primary Endpoint

Met

Outcome Details

SKY-0515-treated patients showed a +1.59-point difference in cUHDRS change from baseline at Month 15 primary timepoint

Importance:6/10

Sentiment:

0.65

Huntington's DiseasePhase 1/2 datacUHDRS endpointclinical trial results

Read the original article

Published by PR Newswire Pharma on September 15, 2026 4:46 PM

Read Original